These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28866467)

  • 21. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA; Stensson A; Schön K; Lycke N
    Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles.
    Saluja V; Visser MR; van Roosmalen ML; Leenhouts K; Huckriede A; Hinrichs WL; Frijlink HW
    Eur J Pharm Biopharm; 2010 Nov; 76(3):470-4. PubMed ID: 20719246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues.
    Eriksson AM; Schön KM; Lycke NY
    J Immunol; 2004 Sep; 173(5):3310-9. PubMed ID: 15322194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity.
    Lycke N; Schön K
    Vaccine; 2001 Mar; 19(17-19):2542-8. PubMed ID: 11257390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted vaccine adjuvants based on modified cholera toxin.
    Lycke N
    Curr Mol Med; 2005 Sep; 5(6):591-7. PubMed ID: 16178769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
    Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects.
    Agren L; Sverremark E; Ekman L; Schön K; Löwenadler B; Fernandez C; Lycke N
    J Immunol; 2000 Jun; 164(12):6276-86. PubMed ID: 10843681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection.
    Bernasconi V; Norling K; Gribonika I; Ong LC; Burazerovic S; Parveen N; Schön K; Stensson A; Bally M; Larson G; Höök F; Lycke N
    Mucosal Immunol; 2021 Mar; 14(2):523-536. PubMed ID: 32807838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
    Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
    Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
    Lycke N
    Curr Opin Mol Ther; 2001 Feb; 3(1):37-44. PubMed ID: 11249730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.
    Saluja V; Amorij JP; van Roosmalen ML; Leenhouts K; Huckriede A; Hinrichs WL; Frijlink HW
    AAPS J; 2010 Jun; 12(2):109-16. PubMed ID: 20058113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
    Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
    Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.
    Cunningham KA; Carey AJ; Lycke N; Timms P; Beagley KW
    J Reprod Immunol; 2009 Jul; 81(1):34-8. PubMed ID: 19501917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
    Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
    Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subtilisin QK-2: secretory expression in Lactococcus lactis and surface display onto gram-positive enhancer matrix (GEM) particles.
    Mao R; Zhou K; Han Z; Wang Y
    Microb Cell Fact; 2016 May; 15():80. PubMed ID: 27176475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.
    Harakuni T; Sugawa H; Komesu A; Tadano M; Arakawa T
    Infect Immun; 2005 Sep; 73(9):5654-65. PubMed ID: 16113283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HA1-2-fljB Vaccine Induces Immune Responses against Pandemic Swine-Origin H1N1 Influenza Virus in Mice.
    Kang X; Yang Y; Jiao Y; Song H; Song L; Xiong D; Wu L; Pan Z; Jiao X
    J Mol Microbiol Biotechnol; 2016; 26(6):422-432. PubMed ID: 27721310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.
    Chowdhury MY; Li R; Kim JH; Park ME; Kim TH; Pathinayake P; Weeratunga P; Song MK; Son HY; Hong SP; Sung MH; Lee JS; Kim CJ
    PLoS One; 2014; 9(4):e94051. PubMed ID: 24714362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.